Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7047MR)

This product GTTS-WQ7047MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD), Diabetic retinopathy research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7047MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4229MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB029
GTTS-WQ12621MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ14765MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ60MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ11775MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MK-3222
GTTS-WQ194MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ11393MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-575
GTTS-WQ2177MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ALT-803
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW